The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings specifically to rule out the presence of amyloid, a hallmark of the disease. “This is another important step toward expanding access to Alzheimer’s disease diagnostic tools,” said our president and chief executive officer @joannepikedrph. The blood test is intended to help primary care physicians determine which patients do not require Alzheimer’s-related follow-up tests, such as PET scans or cerebrospinal fluid analysis. This can significantly improve the diagnostic process by preventing unnecessary specialized testing for individuals whose cognitive issues stem from non-Alzheimer’s causes. The Association is committed to ensuring blood tests are used appropriately and effectively across all care settings. Read our full statement: bit.ly/4oh3Tiu.